AbbVie AndroGel Jury Verdict Targets 'Low T' Promotion
In first bellwether trial in testosterone replacement therapy litigation, jury issues $150m verdict against AbbVie for fraudulent misrepresentation of AndroGel.
In first bellwether trial in testosterone replacement therapy litigation, jury issues $150m verdict against AbbVie for fraudulent misrepresentation of AndroGel.